Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.430
+0.010 (0.70%)
At close: Apr 2, 2025, 4:00 PM
1.364
-0.067 (-4.65%)
After-hours: Apr 2, 2025, 6:43 PM EDT
Cocrystal Pharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
14.55M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
COCP News
- 2 days ago - Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 27 days ago - Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 - GlobeNewsWire
- 3 months ago - Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
- 3 months ago - Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - GlobeNewsWire
- 8 months ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire
- 8 months ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 11 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 1 year ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire